We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





New Imaging-Based Serology Test Platform for COVID-19 to Confirm Activity of SARS-CoV-2 Vaccines

By LabMedica International staff writers
Posted on 02 Feb 2021
A new imaging-based serology test platform could offer a new approach to antibody testing by providing COVID-19 patients, SARS-CoV-2 vaccine recipients with valuable insights into the array of coronavirus antibodies they possess.

Capricor Therapeutics, Inc. More...
(Los Angeles, CA, USA) has received from Johns Hopkins University (Baltimore, MD, USA) a non-exclusive license to intellectual property, know-how and data related to a new imaging-based serology test platform for COVID-19. This platform, which is amenable to a vast array of serology applications, has been applied to the analysis of patient antibodies to multiple SARS-CoV-2 proteins, including spike, nucleocapsid, and membrane.

The study conducted by Johns Hopkins University researchers marks a new approach to serology testing that harnesses the unique ability to human cells to present viral proteins in their native context and native conformation, and thereby captures and quantifies the true spectrum of patient antibodies to pathogen-encoded proteins. In the study designed to interrogate the utility of an imaging-based serology testing platform, patient plasmas were interrogated for the presence of antibodies to the SARS-CoV-2 spike (S), nucleocapsid (N), membrane (M), and other virus-encoded proteins, using genetically engineered cells as solid-phase support for antigen display in their native conformations and environment. The initial focus on detecting antibodies to S, N, and M proteins reflects their importance for the viral replication cycle, their abundance in virus particles, and the inclusion of all multiple proteins in Capricor’s potential SARS-CoV-2 exosome/RNA vaccine and VLP vaccine products.

The technology demonstrates several key advantages of imaging-based serology, which includes in-sample negative controls and gating of signal strength by specificity of signal pattern, capture of antibodies to proteins in their native conformations and environment within human cells, and the potential for simultaneous interrogation of multiple target proteins.

“In the present example, know-how in the areas of basic cell biology and imaging was used to develop a new approach to antibody testing that can provide COVID-19 patients, SARS-CoV-2 vaccine recipients with valuable insights into the array of SARS-CoV-2 antibodies they possess,” said Dr. Linda Marbán, Ph.D., CEO of Capricor. “Furthermore, we plan to convert the current version of the serology test to a multiplexed imaging test for clinical applications within and beyond the scope of SARS-CoV-2, and we intend to explore the potential for partnership opportunities for our COVID-19 technology.”

Related Links:
Capricor Therapeutics, Inc.


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Pan-Cancer Panel
TruSight Oncology 500
New
Integrated Biochemical & Immunological System
Biolumi CX8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.